Geroscience and senolytics

Cellular senescence is neither wear nor death. It is a durable cell-cycle arrest that a cell imposes on itself in response to damage: telomere shortening, DNA breaks, oxidative stress or oncogene activation. The programme runs through the cyclin-dependent kinase inhibitors p16^INK4a and p21, and it is protective — a cell with a damaged genome is guaranteed not to become a tumour. The problem is that it does not then leave.

The harm is the secretome, not the presence#

An arrested cell stays metabolically active and switches to the senescence-associated secretory phenotype, SASP: interleukins IL-6 and IL-1β, chemokines, matrix metalloproteinases, growth factors. Its regulatory core is NF-κB together with the cytosolic cGAS–STING pathway, which senses fragments of the cell’s own DNA that have escaped the nucleus. SASP is why a relatively small number of senescent cells produces a disproportionate effect: the signal is paracrine, it converts healthy neighbours into the same state, and it sustains the chronic sterile inflammation underlying most age-related disease. Transplanting a modest number of senescent cells into young mice reproduces dysfunction phenotypes — the experiment that makes the relationship causal rather than correlational.

Why a senolytic kills rather than treats#

A senescent cell resists its own apoptosis by upregulating anti-apoptotic BCL-2 family proteins, BCL-xL above all, and by leaning on survival signalling nodes. These senescent-cell anti-apoptotic pathways are the target. Dasatinib with quercetin acts on kinase and survival nodes; navitoclax is a direct BCL-2/BCL-xL inhibitor. The defining feature of the class is that the drug does not normalise the cell — it pushes it across a death threshold.

The dosing regimen follows from that pharmacology. Because the effect is a one-off clearance of a population rather than suppression of a process, the drug can be given in short courses with long intervals until the population rebuilds; continuous exposure is unnecessary and harmful. The same logic bounds toxicity: navitoclax causes dose-limiting thrombocytopenia precisely because platelets depend on BCL-xL for survival. Class selectivity is not absolute and is strongly tissue-dependent — senescent fibroblasts, endothelial cells and preadipocytes rely on different combinations of survival pathways, so there is no universal senolytic.

What is unsettled#

The field’s weak point is measurement. Senescence is defined by a set of features rather than one marker: p16^INK4a, β-galactosidase activity at pH 6, absence of proliferation, SASP. None is specific on its own, and there is no reliable clinically usable biomarker of senescent-cell burden in a living human — which makes it hard for a trial to show that the drug did the thing it was given to do. Clinical evidence remains limited to small open-label and early randomised studies in idiopathic pulmonary fibrosis, diabetic kidney disease and osteoarthritis; no senolytic is approved for an age-related indication. And there is a substantive counter-argument: senescent cells contribute to wound healing, limiting fibrosis and tumour suppression, so clearing them indiscriminately is not automatically neutral.